



Announcement Summary

Entity name

PERCHERON THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

21/11/2024

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	unquoted options exercisable at \$0.26 per share on or before 28 November 2029	4,036,487
New class-code to be confirmed	unquoted options exercisable at \$0.39 per share on or before 28 November 2029	4,036,487
New class-code to be confirmed	unquoted options exercisable at \$0.52 per share on or before 28 November 2029	4,036,486

Proposed +issue date

29/11/2024

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

PERCHERON THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

**1.2 Registered Number Type**

ABN

**Registration Number**

41095060745

**1.3 ASX issuer code**

PER

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

21/11/2024

**1.6 The Proposed issue is:**

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?**  
No

Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**  
New class

**Will the proposed issue of this +security include an offer of attaching +securities?**  
No

Details of +securities proposed to be issued

**ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)**

**Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?**  
Yes

**Will the entity be seeking quotation of the 'new' class of +securities on ASX?**  
No

**ASX +security code**

New class-code to be confirmed

**+Security description**

unquoted options exercisable at \$0.26 per share on or before 28 November 2029

**+Security type**

Options

**Number of +securities proposed to be issued**

4,036,487

**Offer price details**

**Are the +securities proposed to be issued being issued for a cash consideration?**  
No

**Please describe the consideration being provided for the +securities**

Payment of lead manager fees as disclosed in the Appendix 3B lodged on 18 October 2024.

**Please provide an estimate of the AUD equivalent of the consideration being**

**provided for the +securities**

0.032000

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

## Options details

<b>+Security currency</b>	<b>Exercise price</b>	<b>Expiry date</b>
AUD - Australian Dollar	AUD 0.2600	29/11/2029

**Details of the type of +security that will be issued if the option is exercised**

PER : ORDINARY FULLY PAID

**Number of securities that will be issued if the option is exercised**

one fully paid ordinary share in PER

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.**

Please see 2024 Percheron Therapeutics Notice of Annual General Meeting  
<https://percherontx.com/investors/asx-announcements/>

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

New class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

## Details of +securities proposed to be issued

**ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)**

**Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Will the entity be seeking quotation of the 'new' class of +securities on ASX?**

No

**ASX +security code**

New class-code to be confirmed

**+Security description**

unquoted options exercisable at \$0.39 per share on or before 28 November 2029

**+Security type**

Options

**Number of +securities proposed to be issued**

4,036,487

**Offer price details****Are the +securities proposed to be issued being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Payment of lead manager fees as disclosed in the Appendix 3B lodged on 18 October 2024

**Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities**

0.025000

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

## Options details

**+Security currency**

AUD - Australian Dollar

**Exercise price**

AUD 0.3900

**Expiry date**

29/11/2029

**Details of the type of +security that will be issued if the option is exercised**

PER : ORDINARY FULLY PAID

**Number of securities that will be issued if the option is exercised**

One fully paid ordinary share in PER

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.**Please see 2024 Percheron Therapeutics Notice of Annual General Meeting  
<https://percherontx.com/investors/asx-announcements/>**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

New class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

## Details of +securities proposed to be issued

**ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)****Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Will the entity be seeking quotation of the 'new' class of +securities on ASX?**

No

**ASX +security code**

New class-code to be confirmed

**+Security description**

unquoted options exercisable at \$0.52 per share on or before 28 November 2029

**+Security type**

Options

**Number of +securities proposed to be issued**

4,036,486

**Offer price details****Are the +securities proposed to be issued being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

Payment of lead manager fees as disclosed in the Appendix 3B lodged on 18 October 2024

**Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities**

0.020000

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

## Options details

**+Security currency**

AUD - Australian Dollar

**Exercise price**

AUD 0.5200

**Expiry date**

29/11/2029

**Details of the type of +security that will be issued if the option is exercised**

PER : ORDINARY FULLY PAID

**Number of securities that will be issued if the option is exercised**

One fully paid ordinary share in PER

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.**Please see 2024 Percheron Therapeutics Notice of Annual General Meeting  
<https://percherontx.com/investors/asx-announcements/>

## Part 7C - Timetable

**7C.1 Proposed +issue date**

29/11/2024



#### Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

Yes

**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

21/11/2024

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

#### Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

#### Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

Unquoted options are being issued pursuant to Resolution 9 as approved by shareholders at the 2024 Percheron Therapeutics AGM held on 21 November 2024 and in accordance with the lead manager fees as disclosed in the App 3B released on 18 October 2024.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**